<?xml version="1.0" encoding="UTF-8"?><!-- This information is licensed under the Queen's Printer License of British Columbia found: www.bclaws.ca/standards/2014/QP-License_1.0.html. Please review the license terms carefully. --><reg_pit xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:fun="http://www.bclaws.ca/xslt/functions" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="344_2012_pit" xsi:noNamespaceSchemaLocation="https://styles.qp.gov.bc.ca/media/REGS-PIT-XSD.xsd">
  <acttitle>Pharmaceutical Services Act</acttitle>
  <title>Drug Price Regulation</title>
  <regnum>344/2012</regnum>
  <change section="1">
    <changenote eff="April 1, 2017">Section 1 (1) definitions "designation period" and "exclusive generic drug" were added by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
  </change>
  <change section="1">
    <changenote eff="April 1, 2019">Section 1 (1) definitions "designation period" and "exclusive generic drug" BEFORE repealed by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:definition id="d0e155">
      <bcl:text>
        <in:term>designation period</in:term> means the specified period for which a generic drug is designated as an exclusive generic drug for an LCA category;</bcl:text>
    </bcl:definition>
    <bcl:definition id="d0e164">
      <bcl:text>
        <in:term>exclusive generic drug</in:term> means the generic drug designated under section 3.1 (1) as the exclusive generic drug for an LCA category;</bcl:text>
    </bcl:definition>
    <changenote eff="April 1, 2019">Section 1 (1) definition of "generic drug inclusion or exclusion" was added by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <changenote eff="April 1, 2019">Section 1 (1) definition of "manufacturer's list price" BEFORE amended by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:definition id="d2e204">
      <bcl:text>
        <in:term>manufacturer's list price</in:term> means the price per unit of a drug, as provided by a manufacturer to the minister in the manner and at the time required by the minister;</bcl:text>
    </bcl:definition>
  </change>
  <change section="3">
    <changenote eff="April 1, 2019">Section 3 (2) (d) was added by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
  </change>
  <change section="3.01">
    <changenote eff="April 1, 2019">Section 3.01 was enacted by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
  </change>
  <change section="3.1">
    <changenote eff="April 1, 2017">Section 3.1 was enacted by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
  </change>
  <change section="3.1">
    <changenote eff="April 1, 2019">Section 3.1 BEFORE repealed by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:section id="d0e579">
      <bcl:marginalnote>Exclusive generic drug in low cost alternative category</bcl:marginalnote>
      <bcl:num>3.1</bcl:num>
      <bcl:subsection id="d0e587">
        <bcl:num>1</bcl:num>
        <bcl:text>For the purposes of the LCA program, the minister may, for a specified period, designate one generic drug as the exclusive generic drug for an LCA category if all of the following apply:</bcl:text>
        <bcl:paragraph id="d0e595">
          <bcl:num>a</bcl:num>
          <bcl:text>all of the generic drugs in the LCA category are provisional drugs;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d0e604">
          <bcl:num>b</bcl:num>
          <bcl:text>the manufacturer's list price for the exclusive generic drug is equal to or less than the maximum accepted list price for drugs in the LCA category;</bcl:text>
        </bcl:paragraph>
        <bcl:paragraph id="d0e613">
          <bcl:num>c</bcl:num>
          <bcl:text>the minister is of the opinion that there will be a sufficient supply of the exclusive generic drug for the entire designation period.</bcl:text>
        </bcl:paragraph>
      </bcl:subsection>
      <bcl:subsection id="d0e623">
        <bcl:num>2</bcl:num>
        <bcl:text>The minister may not specify a designation period, for an exclusive generic drug, that exceeds 12 months.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d0e632">
        <bcl:num>3</bcl:num>
        <bcl:text>If the minister designates a generic drug as the exclusive generic drug for an LCA category, the minister must immediately cancel a determination, made under section 3 (1) (b), to include any other generic drug in the LCA category.</bcl:text>
      </bcl:subsection>
      <bcl:subsection id="d0e641">
        <bcl:num>4</bcl:num>
        <bcl:text>A cancellation under subsection (3) may be made without notice to anyone or an opportunity to be heard.</bcl:text>
      </bcl:subsection>
      <bcl:hnote>[en. B.C. Reg. 266/2016, Sch. 2, s. 2.]</bcl:hnote>
    </bcl:section>
  </change>
  <change section="4">
    <changenote eff="April 1, 2014">Section 4 (2) (a) BEFORE amended by BC Reg <amendingreg>344/2012</amendingreg>, effective April 1, 2014.</changenote>
    <bcl:paragraph id="d2e552">
      <bcl:num>a</bcl:num>
      <bcl:text>for an LCA category consisting of drugs available as oral solids only, 25%;</bcl:text>
    </bcl:paragraph>
  </change>
  <change section="4">
    <changenote eff="April 1, 2019">Section 4 (2) BEFORE amended by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:subsection id="d2e543">
      <bcl:num>2</bcl:num>
      <bcl:text>Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category is the following percentage of the manufacturer's list price, as of the date on which a generic drug is first assigned to the LCA category, for the LCA drug comparator for that LCA category:</bcl:text>
      <bcl:paragraph id="d2e5521">
        <bcl:num>a</bcl:num>
        <bcl:text>for an LCA category consisting of drugs available as oral solids only, 20%;</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e562">
        <bcl:num>b</bcl:num>
        <bcl:text>for any other LCA category, 35%.</bcl:text>
      </bcl:paragraph>
    </bcl:subsection>
    <changenote eff="April 1, 2019">Section 4 (2.1) was added by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
  </change>
  <change section="5">
    <changenote eff="April 1, 2014">Section 5 (2) (a) BEFORE amended by BC Reg <amendingreg>344/2012</amendingreg>, effective April 1, 2014.</changenote>
    <bcl:paragraph id="d2e619">
      <bcl:num>a</bcl:num>
      <bcl:text>if the LCA category consists of drugs available as oral solids only, 25% of the base price set out in Column 2 of the Schedule opposite the LCA category, and</bcl:text>
    </bcl:paragraph>
  </change>
  <change section="5">
    <changenote eff="April 1, 2019">Section 5 (2) BEFORE amended by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:subsection id="d2e610">
      <bcl:num>2</bcl:num>
      <bcl:text>Except as set out in subsection (3), the maximum accepted list price for drugs in an LCA category listed in Column 1 of the Schedule is,</bcl:text>
      <bcl:paragraph id="d2e6191">
        <bcl:num>a</bcl:num>
        <bcl:text>if the LCA category consists of drugs available as oral solids only, 20% of the base price set out in Column 2 of the Schedule opposite the LCA category, and</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e629">
        <bcl:num>b</bcl:num>
        <bcl:text>for any other LCA category, 35% of the base price set out in Column 2 of the Schedule opposite that LCA category.</bcl:text>
      </bcl:paragraph>
    </bcl:subsection>
    <changenote eff="April 1, 2019">Section 5 (4) (b) BEFORE amended by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:paragraph id="d2e668">
      <bcl:num>b</bcl:num>
      <bcl:text>for the purposes of section 4 (2), the date on which a generic drug is first assigned to the LCA category is deemed to be the date on which the minister deems the LCA category to have been established.</bcl:text>
    </bcl:paragraph>
  </change>
  <change section="6">
    <changenote eff="January 1, 2016">Section 6 (1) BEFORE amended by BC Reg <amendingreg>255/2015</amendingreg>, effective January 1, 2016.</changenote>
    <bcl:subsection id="d2e686">
      <bcl:num>1</bcl:num>
      <bcl:text>The following are reference drug categories for the purposes of the reference drug program:</bcl:text>
      <bcl:paragraph id="d2e695">
        <bcl:num>a</bcl:num>
        <bcl:text>angiotensin converting enzyme inhibitors;</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e704">
        <bcl:num>b</bcl:num>
        <bcl:text>dihydropyridine calcium channel blockers;</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e714">
        <bcl:num>c</bcl:num>
        <bcl:text>histamine 2 receptor antagonists;</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e723">
        <bcl:num>d</bcl:num>
        <bcl:text>oral nitrates;</bcl:text>
      </bcl:paragraph>
      <bcl:paragraph id="d2e732">
        <bcl:num>e</bcl:num>
        <bcl:text>non-steroidal anti-inflammatory drugs.</bcl:text>
      </bcl:paragraph>
    </bcl:subsection>
  </change>
  <change section="14">
    <changenote eff="April 1, 2017">Section 14 (1) BEFORE amended by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <bcl:section id="d2e1409">
      <bcl:marginalnote>Designation of provisional drugs</bcl:marginalnote>
      <bcl:num>14</bcl:num>
      <bcl:subsection id="d2e1417">
        <bcl:num>1</bcl:num>
        <bcl:text>The minister may designate a generic drug as a provisional drug if any of the following apply:</bcl:text>
      </bcl:subsection>
    </bcl:section>
    <changenote eff="April 1, 2017">Section 14 (1.1) was added by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <changenote eff="April 1, 2017">Section 14 (2) BEFORE amended by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <bcl:subsection id="d2e1478">
      <bcl:num>2</bcl:num>
      <bcl:text>The minister may cancel a designation made under this section at any time without notice to anyone or an opportunity to be heard.</bcl:text>
    </bcl:subsection>
    <changenote eff="April 1, 2017">Section 14 (3) BEFORE amended by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <bcl:subsection id="d2e1487">
      <bcl:num>3</bcl:num>
      <bcl:text>If a drug's designation as a provisional drug is cancelled under subsection (2), the minister must not list the drug on a formulary before the next April 1, unless section 16 <in:desc>[temporary listing of drugs]</in:desc> applies.</bcl:text>
    </bcl:subsection>
  </change>
  <change section="14">
    <changenote eff="April 1, 2019">Section 14 (1.1) (a) BEFORE repealed by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:paragraph id="d0e1709">
      <bcl:num>a</bcl:num>
      <bcl:text>if the minister has designated, under section 3.1 (1), an exclusive generic drug for an LCA category, the minister must immediately cancel a designation made under this section in respect of any other generic drug assigned to the LCA category;</bcl:text>
    </bcl:paragraph>
    <changenote eff="April 1, 2019">Section 14 (3) BEFORE repealed by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:subsection id="d2e14871">
      <bcl:num>3</bcl:num>
      <bcl:text>If, under subsection (1.1) (a), the minister cancels the designation of a drug that has been assigned to an LCA category, the minister must not list the drug on a formulary during the designation period.</bcl:text>
    </bcl:subsection>
  </change>
  <change section="15">
    <changenote eff="April 1, 2017">Section 15 (3) BEFORE amended by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <bcl:subsection id="d2e1566">
      <bcl:num>3</bcl:num>
      <bcl:text>If a drug's listing is refused or cancelled under subsection (2), the minister must not list the drug on a formulary before the next April 1, unless section 16 <in:desc>[temporary listing of drugs]</in:desc> applies.</bcl:text>
    </bcl:subsection>
  </change>
  <change section="15">
    <changenote eff="April 1, 2019">Section 15 (3) BEFORE repealed by BC Reg <amendingreg>22/2019</amendingreg>, effective April 1, 2019.</changenote>
    <bcl:subsection id="d2e15661">
      <bcl:num>3</bcl:num>
      <bcl:text>During the designation period, the minister must refuse to list on a formulary a drug described in subsection (1) that would be assigned to an LCA category if the minister has designated, under section 3.1 (1), an exclusive generic drug for the LCA category.</bcl:text>
    </bcl:subsection>
  </change>
  <change section="17">
    <changenote eff="March 1, 2014">Section 17 BEFORE amended by BC Reg <amendingreg>344/2012</amendingreg>, effective March 1, 2014.</changenote>
    <section>
      <marginalnote>Manufacturers to sell at new prices</marginalnote>
      <sectionnumber>17</sectionnumber>
      <sectiontext>On or after March 1, 2013, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2013.</sectiontext>
    </section>
  </change>
  <change section="17">
    <changenote eff="January 29, 2016">Section 17 BEFORE amended by BC Reg <amendingreg>10/2016</amendingreg>, effective January 29, 2016.</changenote>
    <bcl:section id="d2e1643">
      <bcl:marginalnote>Manufacturers to sell at new prices</bcl:marginalnote>
      <bcl:num>17</bcl:num>
      <bcl:text>On or after March 1, 2014, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2014.</bcl:text>
      <bcl:hnote>[am. B.C. Reg. 344/2012, s. (c).]</bcl:hnote>
    </bcl:section>
  </change>
  <change part="4">
    <changenote eff="April 1, 2017">Part 4 BEFORE repealed by BC Reg <amendingreg>266/2016</amendingreg>, effective April 1, 2017.</changenote>
    <bcl:part id="d2e1634">
      <bcl:num>4</bcl:num>
      <bcl:text>Sale of Drugs by Manufacturers</bcl:text>
      <bcl:section id="d2e1649">
        <bcl:marginalnote>Manufacturers to sell at new prices</bcl:marginalnote>
        <bcl:num>17</bcl:num>
        <bcl:text>On or after March 1, 2016, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2016.</bcl:text>
        <bcl:hnote>[am. B.C. Regs. 344/2012, s. (c); 10/2016.]</bcl:hnote>
      </bcl:section>
    </bcl:part>
  </change>
</reg_pit>